Literature DB >> 30698999

CRISPR-Based Tools in Immunity.

Dimitre R Simeonov1,2,3, Alexander Marson2,3,4,5,6,7.   

Abstract

CRISPR technology has opened a new era of genome interrogation and genome engineering. Discovered in bacteria, where it protects against bacteriophage by cleaving foreign nucleic acid sequences, the CRISPR system has been repurposed as an adaptable tool for genome editing and multiple other applications. CRISPR's ease of use, precision, and versatility have led to its widespread adoption, accelerating biomedical research and discovery in human cells and model organisms. Here we review CRISPR-based tools and discuss how they are being applied to decode the genetic circuits that control immune function in health and disease. Genetic variation in immune cells can affect autoimmune disease risk, infectious disease pathogenesis, and cancer immunotherapies. CRISPR provides unprecedented opportunities for functional mechanistic studies of coding and noncoding genome sequence function in immunity. Finally, we discuss the potential of CRISPR technology to engineer synthetic cellular immunotherapies for a wide range of human diseases.

Entities:  

Keywords:  CRISPR; autoimmunity; cancer immunotherapy; cell therapy; genetic circuits; genome engineering; immunity

Mesh:

Year:  2019        PMID: 30698999     DOI: 10.1146/annurev-immunol-042718-041522

Source DB:  PubMed          Journal:  Annu Rev Immunol        ISSN: 0732-0582            Impact factor:   28.527


  18 in total

Review 1.  Genome editing to define the function of risk loci and variants in rheumatic disease.

Authors:  Yuriy Baglaenko; Dana Macfarlane; Alexander Marson; Peter A Nigrovic; Soumya Raychaudhuri
Journal:  Nat Rev Rheumatol       Date:  2021-06-29       Impact factor: 20.543

2.  Plasmid- or Ribonucleoprotein-Mediated CRISPR/Cas Gene Editing in Primary Murine T Cells.

Authors:  Marianne Dölz; Romina Marone; Lukas T Jeker
Journal:  Methods Mol Biol       Date:  2021

3.  CRISPR-Cas9 Ribonucleoprotein-Mediated Genomic Editing in Mature Primary Innate Immune Cells.

Authors:  Luke Riggan; Andrew D Hildreth; Marion Rolot; Yung-Yu Wong; William Satyadi; Ryan Sun; Christopher Huerta; Timothy E O'Sullivan
Journal:  Cell Rep       Date:  2020-05-19       Impact factor: 9.423

Review 4.  CRISPR in cancer biology and therapy.

Authors:  Alyna Katti; Bianca J Diaz; Christina M Caragine; Neville E Sanjana; Lukas E Dow
Journal:  Nat Rev Cancer       Date:  2022-02-22       Impact factor: 60.716

5.  Naïve Primary Mouse CD8+ T Cells Retain In Vivo Immune Responsiveness After Electroporation-Based CRISPR/Cas9 Genetic Engineering.

Authors:  Petra Pfenninger; Laura Yerly; Jun Abe
Journal:  Front Immunol       Date:  2022-06-30       Impact factor: 8.786

6.  Lysosomotropic beta blockers induce oxidative stress and IL23A production in Langerhans cells.

Authors:  Gerrit Müller; Charlotte Lübow; Günther Weindl
Journal:  Autophagy       Date:  2019-11-07       Impact factor: 16.016

Review 7.  Deciphering the multifaceted roles of TET proteins in T-cell lineage specification and malignant transformation.

Authors:  Ageliki Tsagaratou
Journal:  Immunol Rev       Date:  2021-01-07       Impact factor: 12.988

8.  CRISPR Screening of CAR T Cells and Cancer Stem Cells Reveals Critical Dependencies for Cell-Based Therapies.

Authors:  Dongrui Wang; Briana C Prager; Christine E Brown; Jeremy N Rich; Ryan C Gimple; Brenda Aguilar; Darya Alizadeh; Hongzhen Tang; Deguan Lv; Renate Starr; Alfonso Brito; Qiulian Wu; Leo J Y Kim; Zhixin Qiu; Peng Lin; Michael H Lorenzini; Behnam Badie; Stephen J Forman; Qi Xie
Journal:  Cancer Discov       Date:  2020-12-16       Impact factor: 39.397

9.  Efficient generation of isogenic primary human myeloid cells using CRISPR-Cas9 ribonucleoproteins.

Authors:  Joseph Hiatt; Devin A Cavero; Michael J McGregor; Weihao Zheng; Jonathan M Budzik; Theodore L Roth; Kelsey M Haas; David Wu; Ujjwal Rathore; Anke Meyer-Franke; Mohamed S Bouzidi; Eric Shifrut; Youjin Lee; Vigneshwari Easwar Kumar; Eric V Dang; David E Gordon; Jason A Wojcechowskyj; Judd F Hultquist; Krystal A Fontaine; Satish K Pillai; Jeffery S Cox; Joel D Ernst; Nevan J Krogan; Alexander Marson
Journal:  Cell Rep       Date:  2021-05-11       Impact factor: 9.423

10.  Efficient gene knockout in primary human and murine myeloid cells by non-viral delivery of CRISPR-Cas9.

Authors:  Emily C Freund; Jaclyn Y Lock; Jaehak Oh; Timurs Maculins; Lelia Delamarre; Christopher J Bohlen; Benjamin Haley; Aditya Murthy
Journal:  J Exp Med       Date:  2020-07-06       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.